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Abstract The detection of Clostridium difficile in previous
studies evaluating antibiotic use as a risk factor was limited to
toxin assay tests. The reported associations may have been
misleading due to the low sensitivity of toxin assay tests
compared to culture results. Antibiotic use and the incidence
of C. difficile of 19 units (wards) over 5 years were analysed.
Stool samples were tested for toxin A/B and cultured. The
correlation of antibiotic use with the incidence of C. difficile
determined by culture results was compared to the correlation
determined by toxin assay results. Additionally, single anti-
biotics were analysed as risk factors. Of 5,772 faecal samples
tested for C. difficile, 154 single-first cases were detected by
the toxin assay and 251 additional single-first cases by
culture. Antibiotic use was a significantly stronger risk factor
in the correlation based on the culture results (R2=0.63)
versus toxin assay results (R2=0.40). Multivariate analysis did
not improve the correlation significantly and only the group
of broad-spectrum beta-lactams was identified as an indepen-
dent risk factor. The correlation between antibiotic use and C.
difficile incidence rates significantly improves if detection is
not limited to faecal toxin assays. Therefore, antibiotic
pressure was previously underestimated as a risk factor.
Introduction
Clostridium difficile is the most common cause of nosoco-
mial diarrhoea. Potential risk factors for the acquisition of
C. difficile and C. difficile infection (CDI) include host
factors, poor infection control practice [1], the use of gastric
acid-suppressive agents [2] and, most importantly, antibi-
otic use [2–5]. Antibiotics may disrupt the host defence
provided by the indigenous micro-flora of the colon and,
therefore, increase the risk of CDI [5]. Historically, the
antibiotics most commonly associated with CDI were
clindamycin, penicillins and cephalosporins, mostly of the
second and third generation [3]. More recently, quinolones
have been identified as a key risk factor resulting in
multiple epidemics and even ward closures [5, 6]. The 2010
guidelines issued by the Society for Healthcare Epidemiol-
ogy of America (SHEA) and the Infectious Diseases
Society of America (IDSA) recommend to minimise
antibiotic use as a preventive measure and, in particular,
to restrict the use of cephalosporins and clindamycin [7].
Toxin assays detect only approximately half of the cases
of C. difficile infections compared to toxigenic culture, as
previously reported in our institution [8]. Therefore,
toxigenic culture, i.e. the detection of toxin A/B in the C.
difficile culture, has recently been described as the gold
standard to diagnose CDI [7, 9]. However, studies reporting
on an association between antibiotic use and the incidence
of C. difficile were based on toxin assay results from faecal
samples [2–4, 10]. Due to the lack of sensitivity of toxin
assays, the reported association might have been under-
estimated and misleading.
We aimed to correlate the unit-specific antibiotic use
with the incidence of C. difficile overall, i.e. faecal toxin
detection and/or positive C. difficile culture. We hypoth-
esised that the inclusion of culture results may strengthen
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the correlation with antibiotic use due to the higher
reliability of detection and that specific classes of antimi-
crobial agents are more significant predictors for colonisa-
tion or infection with C. difficile.
Materials and methods
Setting
The University Hospital Basel is a tertiary care centre
serving 750 beds and about 30,000 admissions per year.
Nineteen units were included in the study (two intensive
care units, one isolation unit, five medical units, eight
surgical units, one neurology unit, one otorhinolaryngology
unit and one dermatology unit). Insufficient data was
available from the gynaecology and obstetrics units, which
were excluded.
Microbiology data
The results of faecal specimens from adult patients
submitted to the laboratory for C. difficile testing over
5 years (January 2004 to December 2008) were prospec-
tively collected. The microbiological tests are described
elsewhere in detail [8]. In short, samples were initially
tested for toxin A/B (CDIFF TOX A/B II; TechLab/
Wampole, Blacksburg, VA, USA) and routinely cultured
for C. difficile (selective cycloserine–cefoxitin–fructose
agar plates).
Pharmacy data
Antibiotic use was collected in defined daily doses (DDD)
as recommended by the World Health Organization (WHO)
since 2003.
Statistical analysis
In order not to violate the assumption of independence of
the single observation, only the first isolate per patient and
year was taken into account to calculate the incidence
densities of C. difficile per 1,000 patient days. The rates
determined by toxin assay alone were compared to the
overall rates, which were based on either a positive C.
difficile culture and/or toxin A/B assay test. The data of 19
units over 5 years allowed the correlation of 95 data points
in ordinary linear regression. Single-sample z-statistics was
performed for the comparison of correlation coefficients.
Because metronidazole and vancomycin use rather repre-
sents the treatment of CDI than being a potential risk factor,
the DDDs of these antibiotics were subtracted from the
overall antibiotic use.
Next, simple linear regression was done for each
antibiotic separately. Furthermore, single-factor and multi-
variate analysis of six groups of antibiotics was performed:
aminoglycosides, quinolones, macrolides/lincosamides,
first- to third-generation cephalosporins, broad-spectrum
beta-lactams (i.e. piperacillin/tazobactam, meropenem, imi-
penem, cefepime) and other beta-lactams.
Additionally, a secondary analysis was completed using a
generalised estimating equation approach on a negative
binomial distribution correcting for repeated measurement/
auto-correlation and for the count nature of the incidence data.
A p-value of ≤0.05 was defined as being statistically
significant. The results were analysed using commercially
available statistical software (SPSS 17.0; SPSS Inc.,
Chicago, IL, USA).
Results
Of 5,772 faecal samples tested during the 5-year study
period, 154 single-first cases of C. difficile were detected
by the toxin assay alone. In addition, 251 single-first cases
of C. difficile were detected by positive C. difficile culture
results (405 cases in total). The corresponding incidence
rates were 0.14 and 0.38 per 1,000 patient days,
respectively.
Antibiotic use correlates significantly with the incidence of
C. difficile in both analyses (p<0.001, Fig. 1). Importantly,
the correlation is significantly better using culture results
than toxin assay results only (R2=0.632 vs. R2=0.397;
p<0.001).
Several antibiotics were identified as risk factors for a
higher incidence of C. difficile overall in the single-factor
analysis: piperacillin/tazobactam (R=0.85), trimethoprim/
sulfamethoxazole (TMP/SMX; R=0.80), cefepime (R=
0.75), meropenem (R=0.81), imipenem/cilastatin (R=
0.38), levofloxacin (R=0.50) and tetracyclines (R=0.23).
Notably, all other antibiotics, including clindamycin and
quinolones other than levofloxacin, were not associated risk
factors. Grouping the antibiotics, the group of broad-
spectrum beta-lactams (R=0.84), aminoglycosides (R=
0.81) and the group of macrolides/lincosamides (R=0.29)
were identified as significant risk factors in the single-factor
analysis. In multivariate analysis, only the groups of
macrolides/lincosamides and broad-spectrum beta-lactams
remained significant independent risk factors for both
outcomes, i.e. the incidence of C. difficile overall and the
incidence determined by toxin assay results only. However,
the goodness of fit of the multivariate model (R2=0.762 and
0.457, respectively) was not significantly better than for the
model with antibiotic use overall as the only predictor.
Importantly, the group of quinolones was not significantly
associated with the incidence of C. difficile in either model.
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Discussion
The correlation between antibiotic use and C. difficile
incidence significantly improves if detection includes
culture results. This study provides new insights in the
correlation of antibiotic use and the incidence of C. difficile,
and has important implications for research and the
(inappropriate) use of antibiotics: antibiotics as a risk factor
were underestimated in the past and, for future research,
cultures should be used to obtain a more appropriate
estimate of antibiotic use as a risk factor for C. difficile.
In addition, the effect of infection control practices may
have been overestimated, since antibiotic use may be more
important than previously thought.
The incidence determined by the results of culture consists
of approximately 40% of cases also detected by the toxin
assay, 40% of cases with toxigenic strains undetected by the
toxin assay and 20% of cases with non-toxigenic strains [8].
Therefore, the increase in the correlation is based on both the
additional number of cases infected by toxigenic strains and
a smaller number of cases colonised by non-toxigenic
strains. Antibiotic pressure selects for C. difficile but is not
restricted to toxin A/B-positive strains. Getting colonised is a
consequence of the predicting factors, but whether one gets
colonised by a toxin-producing or a non-toxigenic strain
might be just a matter of chance and may have further biased
the results in previous studies.
Antibiotics as risk factors were likely underestimated in
studies in the past due to the restriction of detection to toxin
assays, explaining the lower level of correlation in previous
studies [3, 4, 10] or the need to use very sophisticated models
to be able to show similarly strong correlations [2, 4]. The
data shows that a simple model explains more than 60% of
the variance of the incidence of C. difficile using the overall
antibiotic use as a single risk factor. In the single-factor
analysis, the use of certain broad-spectrum beta-lactams, i.e.
piperacillin/tazobactam, cefepime and meropenem, as well as
TMP/SMX and the aminoglycosides, each explained more
than 60% of the variance of C. difficile incidence. In
multivariate analysis, only the groups of macrolides/lincosa-
mides and, most importantly, broad-spectrum beta-lactams
were found to be independent risk factors. In the secondary
analysis, only the latter group remained as an independent
risk factor. Importantly, the predictions in the multivariate
analysis were not significantly better than the prediction
based on the overall antibiotic use as the only risk factor.
Unexpectedly, the association with quinolone use was
not observed in contrast to other reports, e.g. by Pépin [6].
One may hypothesise that quinolones select predominantly
for quinolone-resistant strains such as NAP1/027 and,
consequently, that the lack of a significant association in
this study is due to the comparable low incidence of
quinolone-resistant strains (12.2% of the last 172 isolates
with MHK ≥8 mg/L). Another explanation may be the fact
that the low use of quinolones in our hospital of around 6
DDD/100 patient days may not be sufficient to induce a
higher incidence of C. difficile.
This study adds significantly to previous data limited to
faecal toxin-positive samples showing a correlation between
antibiotic use and the incidence ofC. difficile. For the sake of
simplicity, the results of the ordinary linear regression were
reported. Importantly, our secondary analysis taking into
account repeated measurements and the count nature of the
incidence data corroborated the findings. There are some
limitations to the study. First, the association between
antibiotic use with C. difficile rather than with CDI was
estimated. However, according to our hospital policy, only
loose stool specimens are to be sent to the laboratory for
testing for C. difficile. Second, the multivariate analysis
should be interpreted with caution due to the considerably
Fig. 1 Correlation between unit-specific antibiotic use and the
incidence of Clostridium difficile. Every dot represents one of 95
observations (annual data over 5 years from 19 hospital units). The
straight line represents the line of best fit of the ordinary linear
regression analysis. Antibiotic use refers to the cumulative use of all
antibiotics, with the exception of vancomycin and metronidazole
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low number of observations. Third, the findings are based on
aggregate data, i.e. on the unit level, and caution is warranted
if generalising to the individual level.
In conclusion, the correlation between antibiotic use and
C. difficile incidence rates significantly improves if detec-
tion includes culture results and is not limited to faecal
toxin assays. Hence, antibiotic pressure as a risk factor was
underestimated in previous studies. The results further
underline the importance of the overall pressure of anti-
biotics that explains the majority of the variance of C.
difficile incidence rates rather than the importance of a
single group of antimicrobial agents such as quinolones,
which were not significantly associated. Therefore, inter-
ventions to reduce the overall antibiotic use might be more
successful in controlling C. difficile incidence than inter-
ventions focusing on certain groups of antibiotics.
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